Table 4.
Discounted results
| Scenario | Survival (LY) | Total cost (K€) | ICER (€/LY) versus current | Frontier |
| IndScr only* | 19.4 | 122.6 | Reference | Dominated |
| Pap/Pap-HPV | +10.04 | +22.3 | 22 234 | Dominated |
| Pap/p16Ki67 | +11.68 | +25.5 | 21 918 | Dominated |
| HPV/Pap-3y | +15.93 | +55.8 | 35 095 | Dominated |
| HPV/Pap-5y | +15.89 | −13.3 | Dominant | Ext. Dominated |
| HPV/Pap-10y | +10.51 | −73.4 | Dominant | Reference |
| HPV/p16Ki67-5y | +18.13 | +3.79 | 2091 | 101 389 |
| HPV/p16Ki67-10y | +13.00 | −64.6 | Dominant | 35 846 |
| p16Ki67/p16Ki67 | +18.37 | +160.7 | 87 546 | 6 592 441 |
*Reference for other scenarios. Extra survival per 10 000 women eligible for OS on a lifetime horizon.
HPV, human papillomavirus; ICER, incremental cost-effectiveness ratio; IndScr, individual screening; LY, life years; OS, organised screening; Pap, Papanicolaou.